Skip to content

The Effect of Dexamethasone Administration Route in PENG Block for Pediatric Hip Surgery

The Effect of Dexamethasone Administration Route on Pain and Inflammatory Response in PENG Block for Pediatric Hip Surgery

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06789367
Enrollment
60
Registered
2025-01-23
Start date
2025-02-01
Completion date
2026-03-03
Last updated
2026-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip Disease, Hip Dysplasia

Keywords

pericapsular nerve group block, PENG block, dexamethasone, adjuvant

Brief summary

This study aims to assess the impact of the administration route of dexamethasone (intravenous vs. perineural) on postoperative pain, inflammatory response, and neuromonitoring parameters in pediatric patients undergoing hip surgery. The primary outcome is postoperative pain intensity measured using an age-appropriate pain scale at multiple time intervals. Secondary outcomes include inflammatory markers such as neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), opioid consumption, time to first rescue analgesia, and overall patient recovery. This randomized, double-blinded study seeks to improve pain management strategies and optimize anesthesia protocols in pediatric hip surgery.

Detailed description

Pediatric hip surgery is a complex procedure that can result in significant postoperative pain and an inflammatory response. Effective pain management is critical in this population to promote early mobilization, reduce opioid consumption, and minimize adverse outcomes. The pericapsular nerve group (PENG) block is a regional anesthesia technique that offers targeted analgesia for hip procedures while preserving motor function, making it particularly suitable for pediatric patients. Dexamethasone is commonly used as an adjuvant in regional anesthesia to prolong analgesia and mitigate inflammation. However, the optimal administration route of dexamethasone in the context of PENG block for pediatric hip surgery remains unclear. This study is designed to compare the efficacy of intravenous versus perineural dexamethasone in prolonging postoperative analgesia and reducing inflammatory responses. This prospective, randomized, double-blinded clinical trial will enroll pediatric patients undergoing elective hip surgery. Participants will be randomized into two groups: one group will receive intravenous dexamethasone, while the other will receive perineural dexamethasone administered as part of the PENG block. All patients will receive standardized general anesthesia and PENG block using a local anesthetic at a fixed concentration. The primary outcome will be time to first request rescue analgesia. Secondary outcomes include the inflammatory response measured by NLR and PLR, postoperative pain intensity, assessed using an age-appropriate pain scale at predefined time intervals, total opioid consumption, and blood glucose levels. The study will also monitor neuromonitoring parameters during surgery to ensure patient safety and evaluate the influence of dexamethasone on neurological outcomes. Safety will be closely monitored throughout the study, with particular attention to potential complications such as local anesthetic systemic toxicity (LAST) or dexamethasone-related adverse events.

Interventions

PENG block with 0.5ml/kg 0.2% ropivacaine + 0,1mgkg perineural Dexamethasone

PENG block with 0,5ml/kg 0.2% ropivacaine + 0,1mg/kg intravenous Dexamethasone

Sponsors

Poznan University of Medical Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
3 Months to 6 Years
Healthy volunteers
No

Inclusion criteria

* children scheduled for hip surgery * body weight \> 5kg

Exclusion criteria

* infection at the site of the regional block, * coagulation disorders, * immunodeficiency, * American Society of Anesthesiologists (ASA) physical status of IV or higher, * history of regular steroid medication.

Design outcomes

Primary

MeasureTime frameDescription
Time to first rescue opioid analgesia48 hours after surgeryTime to first rescue opioid analgesia

Secondary

MeasureTime frameDescription
Total opioid consumption48 hours after surgeryTotal opioid consumption in milliequivalents of morphine
NRS4 hours after surgeryThe numeric rating scale (NRS) with zero meaning "no pain" and 10 meaning "the worst pain imaginable."
Nerve damage12 hours after surgeryNerve damage assesent will be performed using scale: N0- no nerve damage; N1- minor - sensory paresthesia; N2- majorcomplete sensory anesthesia; N3- Complete- complete motor defect with or without paraesthesia; N4-CRPS- Complex Regional Pain Syndrome
NLR12 hours after surgeryNeutrophile-to-lymphocyte ratio
PLR12 hours after surgeryPlatelet-to-lymphocyte ratio
glucose12 hours after surgeryblood glucose levels

Countries

Poland

Contacts

STUDY_CHAIRMalgorzata Reysner, M.D. Ph.D.

Poznań University of Medical Sciences

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 17, 2026